Ascendia

  MARKET NEWS

Aerska Launches With $21 Million in Financing to Develop RNAi Medicines for Diseases of the Brain
RheumaGen Announces Oral Presentation on HLA Gene-Editing Preclinical Data for Lead Autoimmune Disease Program at ACR Convergence 2025
Fortress Biotech & Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
Faeth Therapeutics’ R&D Platform Delivers First Cross-Disease Validation Beyond Oncology
VERAXA Biotech & Secarna Pharmaceuticals Initiate Antibody Oligonucleotide Conjugate Alliance in Immunology
Orexo US Awarded $8 Million by BARDA for OX390 Development Partnership
Credence MedSystems & SMC Ltd. Pharma Services Announce Collaboration to Advance Dual Chamber Fill-Finish Capabilities
Harrow to Acquire Melt Pharmaceuticals
Gattefossé Inaugurates New Manufacturing Facility in Texas
AIM ImmunoTech Secures Patent Through 2039 for Novel Cancer Therapy

  EXPERT CONTENT & RESOURCES

Nitrosamine Risk Assessment and Mitigation in Pharmaceutical Products

Nitrosamine Risk Assessment and Mitigation in Pharmaceutical Products

This paper explores practical approaches for identifying and mitigating nitrosamine risks in drug products, integrating emerging tools such as predictive machine learning, advanced nitrite testing methodologies, and strategic excipient sourcing.

CAPMUL GDO (Glycerol Dioleate) is a Versatile Excipient for Pharmaceutical Formulations

CAPMUL GDO (Glycerol Dioleate) is a Versatile Excipient for Pharmaceutical Formulations

ABITEC is excited to present its latest excipient, CAPMUL GDO, Glycerol Dioleate.  CAPMUL GDO is a high-purity, highly versatile functional lipid

The Value of Expertise in Aseptic Fill Finish Manufacturing of Biologics

The Value of Expertise in Aseptic Fill Finish Manufacturing of Biologics

One way to mitigate the risk associated with aseptic fill finish manufacturing of biologics is to partner with a contract manufacturing organization (CMO) demonstrating proven expertise in all aspects of biologics production.

  FEATURED EDITORIAL

  COMPANY PROFILE

At Kindeva, we manufacture more tomorrows for patients worldwide. With best-in-class facilities and comprehensive CDMO services, we offer more than manufacturing—we deliver strategic value. Our global network of 10 manufacturing and R&D sites offer exceptional integrated knowledge and capabilities, including Annex 1-compliant state-of-the-art aseptic fill finish capacity and next-generation sustainable inhalation propellant technology. By combining expertise in injectable, pulmonary, nasal and dermal drug delivery, we help meet the demands of today and deliver the possibilities of tomorrow. Click here for more.

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules

In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.

vytal webinar

WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future

In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine

WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine

By: Dr. Jens Morgenthaler, General Manager and Dr. Matthias Rischer, Head of Innovation, Losan Pharma GmbH

 Introduction

The successful formulation of small molecules is still one of the important challenges of today, especially if these drugs belong to the BioClassificationSystem …

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing

SGS, the world’s leading testing, inspection and certification company, recently announced the release of a new white paper, 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing.

Targeted at researchers, toxicologists and formulation scientists in the clinical and dermatological …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 8 – Prefilled Syringes
October 15 – Injection Devices